Literature DB >> 3284820

Plasma kinin concentration in deoxycorticosterone-salt hypertension.

M Nakagawa1, A Nasjletti.   

Abstract

We investigated the status of circulating kinins in rats with severe hypertension caused by drinking 1% NaCl (saline) and treatment with deoxycorticosterone (DOC, 25 mg/kg/wk s.c.) for 5 weeks. Saline-drinking rats treated with DOC had a higher systolic blood pressure (210 +/- 4 mm Hg) than did rats without DOC treatment drinking water (138 +/- 3 mm Hg) or saline (141 +/- 3 mm Hg). The concentration of kinins in the inferior vena cava plasma of DOC-salt hypertensive rats did not differ from the venous plasma kinin concentration in normotensive rats drinking water or saline. In contrast, the arterial plasma kinin concentration in DOC-salt hypertensive rats (7.0 +/- 0.8 pg/ml) was lower (p less than 0.002) than that in water-drinking controls (14.0 +/- 2.2 pg/ml); it also was lower (p less than 0.005) in saline-drinking rats (8.1 +/- 0.9 pg/ml) than in water-drinking controls. Infusion of bradykinin (20 micrograms/kg/min i.v.) increased arterial plasma kinins in all the groups. Nonetheless, the arterial plasma kinin concentration achieved during bradykinin infusion in DOC-salt hypertensive (1590 +/- 130 pg/ml) and in saline-drinking rats (1540 +/- 100 pg/ml) was lower than that in water-drinking rats (2140 +/- 210 pg/ml). On the other hand, during infusion of the kininase II inhibitor captopril (80 micrograms/hr i.p.) for 3 days, neither DOC-salt hypertensive rats nor saline-drinking normotensive rats exhibited significant reduction of arterial plasma kinins relative to the level in water-drinking controls. These data indicate that high salt intake, irrespective of the level of blood pressure, causes the arterial plasma concentration of kinins to fall.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3284820     DOI: 10.1161/01.hyp.11.5.411

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  5 in total

1.  Antifibrotic effects of N-acetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats.

Authors:  H Peng; O A Carretero; L Raij; F Yang; A Kapke; N E Rhaleb
Journal:  Hypertension       Date:  2001-02       Impact factor: 10.190

2.  Effect of prolonged administration of a urinary kinase inhibitor, ebelactone B on the development of deoxycorticosterone acetate-salt hypertension in rats.

Authors:  H Ito; M Majima; S Nakajima; I Hayashi; M Katori; T Izumi
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

Review 3.  Long-range safety and protective benefits of angiotensin-converting enzyme inhibitors for hypertension. Do we need more clinical trials?

Authors:  M P Sambhi; H Gavras; J I Robertson; W M Smith
Journal:  West J Med       Date:  1993-03

Review 4.  The kallikrein-kinin system as a regulator of cardiovascular and renal function.

Authors:  Nour-Eddine Rhaleb; Xiao-Ping Yang; Oscar A Carretero
Journal:  Compr Physiol       Date:  2011-04       Impact factor: 9.090

Review 5.  Role of Kinins in Hypertension and Heart Failure.

Authors:  Suhail Hamid; Imane A Rhaleb; Kamal M Kassem; Nour-Eddine Rhaleb
Journal:  Pharmaceuticals (Basel)       Date:  2020-10-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.